New Breakthrough Therapy Designated for Thyroid Cancer and NSCLC

New Breakthrough Therapy Designated for Thyroid Cancer and NSCLC  Cancer NetworkLOXO-292 Granted Breakthrough Designation for Thyroid Cancer  Curetoday.comNew RET Inhibitors Show Reduced Toxicities in Thyroid Cancer  MedscapeFull coverage

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2OZBeCy